Category:

Carlos Torrado, PharmD, JD, PRS explains the training pharmacists receive with respect to prescriptions for controlled substances.

Justin Gallagher, associate publisher of The American Journal of Managed Care. Welcome to This Week in Managed Care, From the Managed Markets News Network.

Drug Channels Institute...released its...in-depth analysis of the highly dynamic prescription drug distribution industry...2016–17 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors reveals how list price increases of brand-name drugs are boosting the industry’s revenues, even as changes in the U.S. healthcare system threaten wholesalers’ profits...We project that U.S. drug distribution revenues at the Big Three public wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—will exceed $400 billion in 2016...But any change in drug price inflation rates or in manufacturers’ rebate strategy will be very negative for wholesalers’ future revenues and profits...Consolidation among pharmacies and hospitals is making it difficult for wholesalers to capture value and profits from the booming specialty drug market...And contrary to many people’s expectations, specialty biosimilar drugs seem poised to deliver only minimal incremental profits for wholesalers...

Kelly Walsh, PTNN. This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy, describes how pharmacy school curriculums have changed.

Kelly Walsh, PTNN. This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.

Justin Gallagher, associate publisher of The American Journal of Managed Care. Welcome to This Week in Managed Care, From the Managed Markets News Network.

Not everyone reacts to the same medication in the same way...Benedryl makes some people drowsy and others wired. Antidepressants have no affect on 38 percent of patients...Some people are more susceptible to addiction from pain medications while others get pain relief without getting hooked...MD Labs is part of a new industry called pharmacogenetics that uses genetics to map specific genes involved in the metabolism of and response to specific drugs...Ruttledge and Denis Grizelj, co-founder and CEO, began MD Labs in 2011 as a toxicology testing facility for physicians nationwide. They expanded to pharmacogenetic testing in 2014, with the development of their proprietary genetic test Rxight, which maps genes that affect more than 200 medications...Because it’s genetically based, Rxight is a once-in-a-lifetime test...Preemptive testing makes the patient’s genetically-based profile of drug reactions available to doctors and pharmacists before illness strikes and before a drug is prescribed...MD Labs contracts with Saint Mary’s Health to offer the testing and consultation at both Saint Mary’s Regional Medical Center and Saint Mary’s Medical Group Primary Care Northwest Reno...Pharmacists at those locations are Rxight Certified to administer the test and provide consultation...Nationwide the company has 100-110 employees total, which includes about 55 people in the Reno office plus a sales force in offices in Chicago and Pennsylvania...MD Labs owners see a future in which pharmacogenetics testing is routine.

Justin Gallagher, associate publisher of The American Journal of Managed Care. Welcome to This Week in Managed Care, From the Managed Markets News Network.

Raia Drogasil SA, Brazil's biggest drugstore chain, will sit out expected consolidation of the national market, the company's chief executive said in an interview, because its own rapidly expanding network is proving increasingly efficient...There has been no lack of buyers and sellers in the market. CVS Health Corp entered Brazil with an acquisition in 2013 and...rival Brasil Pharma SA is close to selling two units..."Our growth is organic,"..."Our aim is to consolidate the market opening stores."…Raia Drogasil has done that at an accelerating pace. In July, the company announced plans to open 200 new stores both this year and next…The company had 1,330 stores in Brazil at the end of June...Encouraged by the healthy growth and solid results despite an economic recession in Brazil, investors sent Raia Drogasil shares soaring more than 90 percent this year...